Skip to main content

Metabolomics Tech Licenses Pre-Colorectal Cancer Test

NEW YORK (360Dx) – Metabolomics Technologies today said it has inked a multiyear, non-exclusive licensing and distribution deal with Evolution Laboratories for Metabolomics' pre-colorectal cancer test. 

PolypDx is a urine-based diagnostic test for detecting adenomatous polyps, the precursor to colorectal cancer. Metabolomics said that a clinical trial of almost 1,000 patients demonstrated that the test has higher sensitivity than current fecal-based screening tests for detecting adenomatous polyps. If a patient presents a risk for the polys, they can be directed to colonoscopy, during which the polyps can be removed. 

In May 2016, Metabolomics and Atlantic Diagnostic Laboratories reached an agreement providing access to PolypDx in 12 US states. The deal announced today, and in association with diagnostic testing service firm Lab Express, makes PolypDx available to five additional states: Nevada, California, Arizona, Utah, and Texas.

Further details of the agreement were not disclosed. 

Metabolomics Technologies, based in Edmonton, Alberta, develops metabolomics-based diagnostics. Evolution Labs, based in Wyoming provides diagnostic testing.